Recently, Novo Nordisk (NVO) reported solid top-line results from three phase III studies of Degludec and two studies of DegludecPlus. Degludec significantly reduced the risk of hypoglycaemia during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results